STOCK TITAN

Nkarta, Inc. - NKTX STOCK NEWS

Welcome to our dedicated page for Nkarta news (Ticker: NKTX), a resource for investors and traders seeking the latest updates and insights on Nkarta stock.

Nkarta, Inc. (Nasdaq: NKTX) is a pioneering clinical-stage biotechnology company located in South San Francisco, California. Founded in 2015, Nkarta leverages proprietary natural killer (NK) cell expansion and engineering technologies to develop next-generation immunotherapies for the treatment of cancer and autoimmune diseases. The company’s mission is to harness the innate power of NK cells, which are the body's first line of defense, to create treatments that are more potent, better tolerated, and readily available to a broad patient population.

The core focus of Nkarta lies in its two lead candidates, NKX101 and NKX019. NKX101 is an off-the-shelf immunotherapy that targets NKG2D ligands on tumor cells, using engineered NK cells derived from healthy donors. This candidate shows promising results in treating acute myeloid leukemia (AML), with complete responses observed in high-risk patients. NKX019 targets CD19, a biomarker for B cell malignancies and autoimmune diseases such as lupus nephritis. This candidate has been designed to provide enhanced tumor cell targeting and greater persistence and activity.

Nkata's technological platform combines NK cell expansion and cryopreservation with advanced cell engineering techniques, including CRISPR-based genome engineering. This ensures a robust supply of NK cells and enables precise modification for enhanced therapeutic effectiveness. The company's cell therapies aim to be accessible for broad outpatient treatment, offering off-the-shelf solutions that minimize patient burden and reduce treatment delays.

Recent milestones include the clearance of an Investigational New Drug (IND) application by the U.S. FDA to evaluate NKX019 for lupus nephritis, expansion of their pipeline into autoimmune diseases, and strategic financial moves to extend their cash runway into 2026. Nkarta continues to provide updates on its clinical programs and looks forward to presenting additional data throughout 2024.

The company's financial backing comes from prominent investors such as SR One, NEA, and Novo Ventures, which underscores confidence in Nkarta's potential to revolutionize cell therapy. With a commitment to rigorous clinical development and strategic resource allocation, Nkarta is well-positioned to advance its innovative cell therapy candidates and deliver transformative treatments to patients in need.

Rhea-AI Summary

Nkarta, Inc. (Nasdaq: NKTX) reported its third-quarter 2021 results, highlighting key advancements in its clinical trials. The company anticipates initial data from the Phase 1 trial of NKX101 in AML and MDS in the first half of 2022, while also announcing the successful dosing of patients in the NKX019 trial for B cell malignancies. Financially, Nkarta had cash equivalents of $259.8 million as of September 30, 2021, with R&D expenses totaling $16.6 million. The net loss for the quarter was $22.4 million, or $0.68 per share, but guidance suggests operational funding through at least the second half of 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.61%
Tags
-
Rhea-AI Summary

Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical firm focused on engineered NK cell therapies for cancer, announced its participation in several upcoming investor conferences. Notable events include the Cowen 5th Annual IO Next Summit on November 15, 2021, at 11:15 a.m. ET, the Stifel 2021 Virtual Healthcare Conference on November 17, 2021, at 2:00 p.m. ET, and the Evercore ISI 4th Annual HealthCONx Conference on December 1, 2021, at 4:20 p.m. ET. Each session will be webcast live and available for replay on Nkarta's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.61%
Tags
conferences
-
Rhea-AI Summary

Nkarta, Inc. announced the initiation of a Phase 1 clinical trial for NKX019 aimed at treating advanced B-cell malignancies. This investigational NK cell immunotherapy targets CD19, with initial data expected in 2022. The company also updated its timeline for NKX101, another CAR NK cell therapy for AML and MDS, anticipating initial data in the first half of 2022. Nkarta is producing the NKX019 clinical supply at its South San Francisco facility, aiming to provide an effective off-the-shelf treatment option for patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-27.57%
Tags
Rhea-AI Summary

Nkarta, Inc. (Nasdaq: NKTX) announced four upcoming presentations at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting, detailing advancements in engineered natural killer (NK) cell therapies. Key highlights include the potential clinical applications of CRISPR/Cas9 technologies and donor selection algorithms for next-generation NK cells. The presentations aim to enhance the expansion of engineered NK cells, potentially allowing a single donor to supply a lifetime's worth of commercial product. Full abstracts will be available on November 9, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.34%
Tags
conferences clinical trial
-
Rhea-AI Summary

Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company focused on NK cell therapies for cancer, announced participation in the Cantor Virtual Global Healthcare Conference on September 28, 2021, at 4:00 p.m. ET. A live webcast of the presentation will be accessible on Nkarta’s website, with an archived replay available for approximately four weeks. Nkarta is committed to developing off-the-shelf NK cell therapies through innovative manufacturing and engineering techniques to enhance tumor targeting and sustained activity in cancer patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
conferences
-
Rhea-AI Summary

Nkarta, Inc. (Nasdaq: NKTX) reported its Q2 2021 results, highlighting progress in NK cell therapies. The company aims to present initial data from its NKX101 clinical trial by year's end, while patient dosing for NKX019 is expected to begin in 2H 2021. Nkarta has formed a collaboration with CRISPR Therapeutics for developing gene-edited therapies and established a new manufacturing headquarters to support trial and commercial efforts. As of June 30, 2021, cash reserves stood at $280.3 million, with a net loss of $21.5 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
Rhea-AI Summary

Nkarta, Inc. (Nasdaq: NKTX) has signed a lease for an 88,000 square foot facility in South San Francisco, intended for scaled manufacturing and to serve as the company headquarters. This expansion aims to support Nkarta’s engineering NK cell therapy candidates and enhance clinical programs NKX101 and NKX019. The facility, expected to be operational by late 2023, will enable commercial-scale production for clinical trials. Nkarta's focus on cost-effective therapies aligns with their goal to improve access for cancer patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
none
-
Rhea-AI Summary

Nkarta, a biopharmaceutical company focused on developing engineered natural killer (NK) cell therapies for cancer, announced its participation in the Raymond James Human Health Innovation Conference. The event is scheduled for June 21, 2021, featuring a fireside chat presentation at 3:20 p.m. ET. A live webcast will be available on Nkarta's website, with a replay accessible for approximately four weeks thereafter. The company is advancing allogeneic NK cell therapies through innovative manufacturing processes designed to enhance tumor targeting and persistence.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.34%
Tags
conferences
-
Rhea-AI Summary

Nkarta, Inc. (Nasdaq: NKTX) announced that CEO Paul Hastings has been elected Chair of the Biotechnology Innovation Organization (BIO) Board of Directors for the 2021-2022 term. Hastings, recognized as a biotech pioneer, has a history as a patient advocate and innovative leader. BIO, the largest biotechnology advocacy group, focuses on advancing healthcare and environmental products. Hastings' election is expected to enhance support for innovation and advocacy within the biotech industry, as he brings over two decades of leadership experience to his new role.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.19%
Tags
none
Rhea-AI Summary

Nkarta, Inc. (Nasdaq: NKTX) announced its participation in the Jefferies Virtual Healthcare Conference on June 2, 2021, at 3:30 p.m. ET. The company focuses on developing engineered natural killer (NK) cell therapies for cancer treatment. A live webcast of the presentation will be available on the company’s website, with a replay accessible for four weeks. Nkarta aims to enhance tumor targeting through its proprietary technologies and efficient manufacturing processes, advancing its pipeline of allogeneic NK cell therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.32%
Tags
none

FAQ

What is the current stock price of Nkarta (NKTX)?

The current stock price of Nkarta (NKTX) is $2.5 as of January 3, 2025.

What is the market cap of Nkarta (NKTX)?

The market cap of Nkarta (NKTX) is approximately 176.8M.

What does Nkarta, Inc. specialize in?

Nkarta, Inc. specializes in developing engineered natural killer (NK) cell therapies for the treatment of cancer and autoimmune diseases.

Where is Nkarta, Inc. located?

Nkarta, Inc. is located in South San Francisco, California.

What are Nkarta's lead therapy candidates?

Nkarta's lead therapy candidates are NKX101, which targets NKG2D ligands on tumor cells for AML treatment, and NKX019, a CD19-directed CAR NK cell therapy for B cell malignancies and autoimmune diseases like lupus nephritis.

How does Nkarta source its NK cells?

Nkarta sources its NK cells from the peripheral blood of healthy adult donors and utilizes proprietary technologies for their expansion and engineering.

What are the recent achievements of Nkarta?

Recent achievements include FDA clearance for an IND application to evaluate NKX019 for lupus nephritis, pipeline expansion into autoimmune diseases, and strategic financial moves to extend operational runway into 2026.

Who are some of Nkarta's investors?

Nkarta's investors include SR One, NEA, and Novo Ventures.

How does Nkarta ensure its therapies are readily available?

Nkarta ensures therapies are readily available by developing off-the-shelf solutions that are cryopreserved and can be administered in outpatient settings, minimizing patient burden and treatment delays.

What is the focus of Nkarta's NKX019 therapy?

NKX019 is focused on treating B cell malignancies and autoimmune diseases by targeting the CD19 biomarker, offering enhanced tumor cell targeting and greater persistence.

What technological platforms does Nkarta use?

Nkarta uses NK cell expansion and cryopreservation platforms combined with cell engineering technologies and CRISPR-based genome engineering.

What future updates is Nkarta expected to provide?

Nkarta is expected to provide updates on its clinical programs, including data from NKX101 and NKX019 trials, throughout 2024.
Nkarta, Inc.

Nasdaq:NKTX

NKTX Rankings

NKTX Stock Data

176.77M
65.43M
4.87%
99.79%
9.42%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SOUTH SAN FRANCISCO